| Early versus late opening of coronary arteries: the effect of timing. | |
| | |
MedLine Citation:
|
PMID: 2145108 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Intuitively, one would assume that the benefit from the use of thrombolytic therapy in reducing mortality in acute myocardial infarction (AMI) is directly related to early recanalization of the thrombosed infarct-related artery. However, a meta-analysis of early clinical trials and the ISIS-II trial results suggests that thrombolysis initiated between 6 and 24 h after the onset of infarction still reduces mortality. Verification of this observation is currently being sought in three ongoing trials of late reperfusion. These are the EMERA trial in South America, using streptokinase; the LATE study involving several European countries, the United States, Canada, and Australia, using tissue plasminogen activator (tPA); and the TAMI-6 trial, in which either tPA or placebo is given 6 to 24 h postinfarction, and patients with closed infarct-related arteries are randomized further to either angioplasty or no angioplasty. There are theoretical reasons that late reperfusion may be beneficial. These reasons include the prevention of infarct expansion and ventricular remodeling leading to ventricular dilatation, the provision of electrophysiologic stability lessening the likelihood of malignant ventricular arrhythmias, and the ability of collaterals emanating from the recanalized artery to perfuse ischemic but still viable myocardium. There are also reasons that late reperfusion might be harmful, including myocardial stunning, microvascular damage, and intramyocardial hemorrhage leading to an increased likelihood of myocardial rupture. It does appear, however, that once recanalization occurs, maintenance of patency improves late outcome, as shown in the Western Washington Intracoronary Streptokinase Trial, the TAMI trial, the TIMI trial, and the Duke study.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
E Rapaport |
Related Documents
:
|
11757728 - Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. 1617708 - Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokina... 14752128 - Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in ac... 12103258 - Evaluation of the time saved by prehospital initiation of reteplase for st-elevation my... 19162988 - Online cardiac arrhythmia classification by means of circle maps analysis implemented o... 6496178 - The effects of a highly purified hyaluronidase preparation on experimental myocardial i... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis |
Journal Detail:
|
Title: Clinical cardiology Volume: 13 ISSN: 0160-9289 ISO Abbreviation: Clin Cardiol Publication Date: 1990 Aug |
Date Detail:
|
Created Date: 1990-11-06 Completed Date: 1990-11-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: VIII18-22 Citation Subset: IM |
Affiliation:
|
Cardiology Division, San Francisco General Hospital, CA 94110. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Humans Meta-Analysis as Topic Myocardial Infarction / drug therapy* Myocardial Reperfusion / methods Streptokinase / therapeutic use Thrombolytic Therapy* Time Factors Tissue Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogeno...
Next Document: T-lymphocyte subsets as noninvasive markers of cardiomyopathy.